• About us
• Contact

Advertisement

Organisation › Details

Cellzome GmbH [old]

https://www.cellzome.com
Link has been incorrect on 2014-05-13

Cellzome is a world leader in chemoproteomics, transforming the sciences of epigenetics and signal transduction into novel drug candidates in inflammatory diseases and oncology. The Company maintains the highest levels of scientific expertise and has active collaborations with the foremost academic laboratories around the world. Cellzome's technologies work with native proteins in a physiological setting to discover small molecule drugs targeting protein complexes that underlie diseases. The Company has a track record in delivering significant collaborations with top pharmaceutical companies including GlaxoSmithKline, Johnson & Johnson and Novartis. Cellzome is a privately-held, international, company located in Heidelberg, Germany and Cambridge, UK employing about 100 people, of which 65% are women. *

 

	Start	2000-01-01 established
	End	renamed
	Group	GSK (Group)
	Today	Cellzome GmbH, a GSK company
	Predecessor	EMBL (European Molecular Biology Laboratory)
	Successor	Cellzome AG
	Industry	proteomics
	Person	Neubauer, Gitte (Cellzome 2000 Founder)
	Region	Heidelberg
	Country	Germany
	City	69117 Heidelberg
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2025-03-16

Advertisement

More documents for GSK (Group)

• [1] GSK plc. (1/13/25). "Press Release: GSK Enters Agreement to Acquire IDRx, Inc.". London....
• [2] IDRx, Inc.. (8/7/24). "Press Release: IDRx Announces $120 Million Series B Financing to Advance Potential Best-in-class New Treatment for Gastrointestinal Stromal Tumor (GIST)". Plymouth, MA....
• [3] CureVac N.V.. (7/3/24). "Press Release: GSK and CureVac to Restructure Collaboration into New Licensing Agreement". London, Tübingen & Boston, MA....
• [4] CureVac N.V.. (5/28/24). "Press Release: CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK". Tübingen & Boston, MA....
• [5] BioVersys AG. (5/7/24). "Press Release: BioVersys Announces Expansion of Strategic Collaboration with GSK and Extension of its Series C Round by CHF 12.3 Million". Basel....
• [6] IDRx, Inc.. (3/12/24). "Press Release: IDRx Strengthens Executive Team with Appointments of Tim Clackson, Ph.D., as CEO and Brad Dahms as CFO and CBO". Plymouth, MA....
• [7] CureVac N.V.. (1/5/24). "Press Release: CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform". Tübingen & Boston, MA....
• [8] LimmaTech Biologics AG. (7/20/23). "Press Release: GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine". Schlieren....
• [9] CureVac N.V.. (1/6/23). "Press Release: CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs". Tübingen & Boston, MA....
• [10] Valneva S.E.. (11/17/22). "Press Release: Valneva Appoints Dipal Patel as Chief Commercial Officer". Saint-Herblain....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.